vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and KFORCE INC (KFRC). Click either name above to swap in a different company.
KFORCE INC is the larger business by last-quarter revenue ($330.4M vs $196.0M, roughly 1.7× Axsome Therapeutics, Inc.). KFORCE INC runs the higher net margin — 2.4% vs -14.6%, a 17.0% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 0.1%). KFORCE INC produced more free cash flow last quarter ($-7.4M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -3.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
AXSM vs KFRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $330.4M |
| Net Profit | $-28.6M | $7.9M |
| Gross Margin | — | 27.3% |
| Operating Margin | -13.8% | 3.6% |
| Net Margin | -14.6% | 2.4% |
| Revenue YoY | 65.0% | 0.1% |
| Net Profit YoY | 61.9% | -2.7% |
| EPS (diluted) | $-0.55 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $330.4M | ||
| Q4 25 | $196.0M | $332.0M | ||
| Q3 25 | $171.0M | $332.6M | ||
| Q2 25 | $150.0M | $334.3M | ||
| Q1 25 | $121.5M | $330.0M | ||
| Q4 24 | $118.8M | $343.8M | ||
| Q3 24 | $104.8M | $353.3M | ||
| Q2 24 | $87.2M | $356.3M |
| Q1 26 | — | $7.9M | ||
| Q4 25 | $-28.6M | $5.2M | ||
| Q3 25 | $-47.2M | $11.1M | ||
| Q2 25 | $-48.0M | $10.4M | ||
| Q1 25 | $-59.4M | $8.1M | ||
| Q4 24 | $-74.9M | $11.1M | ||
| Q3 24 | $-64.6M | $14.2M | ||
| Q2 24 | $-79.3M | $14.2M |
| Q1 26 | — | 27.3% | ||
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 27.7% | ||
| Q2 25 | — | 27.1% | ||
| Q1 25 | — | 26.7% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 27.9% | ||
| Q2 24 | — | 27.8% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | -13.8% | 2.6% | ||
| Q3 25 | -27.0% | 4.5% | ||
| Q2 25 | -24.5% | 4.5% | ||
| Q1 25 | -46.9% | 3.5% | ||
| Q4 24 | -61.1% | 4.5% | ||
| Q3 24 | -59.8% | 5.3% | ||
| Q2 24 | -89.5% | 5.5% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | -14.6% | 1.6% | ||
| Q3 25 | -27.6% | 3.3% | ||
| Q2 25 | -32.0% | 3.1% | ||
| Q1 25 | -48.9% | 2.5% | ||
| Q4 24 | -63.1% | 3.2% | ||
| Q3 24 | -61.7% | 4.0% | ||
| Q2 24 | -91.0% | 4.0% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | $-0.55 | $0.29 | ||
| Q3 25 | $-0.94 | $0.63 | ||
| Q2 25 | $-0.97 | $0.59 | ||
| Q1 25 | $-1.22 | $0.45 | ||
| Q4 24 | $-1.54 | $0.60 | ||
| Q3 24 | $-1.34 | $0.75 | ||
| Q2 24 | $-1.67 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $117.4M |
| Total Assets | $689.8M | $384.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3M | ||
| Q4 25 | $322.9M | $2.1M | ||
| Q3 25 | $325.3M | $1.3M | ||
| Q2 25 | $303.0M | $2.5M | ||
| Q1 25 | $300.9M | $444.0K | ||
| Q4 24 | $315.4M | $349.0K | ||
| Q3 24 | $327.3M | $127.0K | ||
| Q2 24 | $315.7M | $110.0K |
| Q1 26 | — | $117.4M | ||
| Q4 25 | $88.3M | $124.6M | ||
| Q3 25 | $73.7M | $132.1M | ||
| Q2 25 | $73.1M | $134.4M | ||
| Q1 25 | $53.2M | $138.0M | ||
| Q4 24 | $57.0M | $154.6M | ||
| Q3 24 | $92.9M | $167.4M | ||
| Q2 24 | $102.9M | $166.6M |
| Q1 26 | — | $384.8M | ||
| Q4 25 | $689.8M | $365.6M | ||
| Q3 25 | $669.3M | $374.2M | ||
| Q2 25 | $639.8M | $373.6M | ||
| Q1 25 | $596.7M | $368.2M | ||
| Q4 24 | $568.5M | $357.8M | ||
| Q3 24 | $561.5M | $369.9M | ||
| Q2 24 | $548.2M | $362.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | $-7.4M |
| FCF MarginFCF / Revenue | -9.6% | -2.2% |
| Capex IntensityCapex / Revenue | 0.0% | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $19.7M | ||
| Q3 25 | $1.0M | $23.3M | ||
| Q2 25 | $-32.4M | $18.4M | ||
| Q1 25 | $-43.4M | $249.0K | ||
| Q4 24 | $-26.2M | $21.8M | ||
| Q3 24 | $-18.6M | $31.0M | ||
| Q2 24 | $-30.1M | $20.9M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | $-18.7M | $16.7M | ||
| Q3 25 | $988.0K | $19.8M | ||
| Q2 25 | $-32.4M | $14.2M | ||
| Q1 25 | $-43.7M | $-3.9M | ||
| Q4 24 | $-26.2M | $20.9M | ||
| Q3 24 | $-18.7M | $27.5M | ||
| Q2 24 | $-30.2M | $17.8M |
| Q1 26 | — | -2.2% | ||
| Q4 25 | -9.6% | 5.0% | ||
| Q3 25 | 0.6% | 6.0% | ||
| Q2 25 | -21.6% | 4.3% | ||
| Q1 25 | -36.0% | -1.2% | ||
| Q4 24 | -22.1% | 6.1% | ||
| Q3 24 | -17.9% | 7.8% | ||
| Q2 24 | -34.6% | 5.0% |
| Q1 26 | — | 1.0% | ||
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.3% | 1.3% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.1% | 1.0% | ||
| Q2 24 | 0.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | — | 2.11× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 1.97× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
